Breaking News Instant updates and real-time market news.

CELG

Celgene

$118.51

-3.62 (-2.96%)

, ZTS

Zoetis

09:28
12/01/16
12/01
09:28
12/01/16
09:28

Celgene, Zoetis among top healthcare picks at William Blair

William Blair analysts named their top health care picks for 2017, identifying Evolent Health (EVH) as their top HC Services and HC IT pick, Zoetis (ZTS) as their top dental and animal health pick,and Pacific Biosciences (PACB) as their top diagnostic services and life sciences choice, The firm identified ARIAD (ARIA), Celgene (CELG) and SAGE Therapeutics (SAGE) as their top biotech choices. It named Edwards Lifesciences (EW), Nevro (NVRO), and K2M Group (KTWO) as its favorite med tech picks.

CELG

Celgene

$118.51

-3.62 (-2.96%)

ZTS

Zoetis

EVH

Evolent Health

PACB

Pacific Biosciences

$7.61

-0.09 (-1.17%)

ARIA

Acquired by TKPYY 2/17

$13.48

-0.32 (-2.32%)

SAGE

Sage Therapeutics

$50.11

-0.69 (-1.36%)

EW

Edwards Lifesciences

NVRO

Nevro

KTWO

K2M Group

$18.80

0.11 (0.59%)

  • 01

    Dec

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 04

    Dec

  • 04

    Dec

  • 06

    Dec

  • 07

    Dec

  • 08

    Dec

  • 12

    Dec

  • 14

    Dec

  • 29

    Apr

CELG Celgene
$118.51

-3.62 (-2.96%)

11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."
11/09/16
STPT
11/09/16
DOWNGRADE
STPT
Hold
Celgene downgraded to Hold from Buy at Standpoint Research
11/28/16
OPCO
11/28/16
INITIATION
Target $141
OPCO
Outperform
Celgene initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leah Cann initiated Celgene with an Outperform rating and $141 price target, estimating that revenue will grow at a compound annual growth rate of 19% per year for the next five years and that its GAAP EPS can grow by a 31% CAGR over the same span.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
ZTS Zoetis

09/29/16
BOFA
09/29/16
INITIATION
Target $60
BOFA
Buy
Zoetis reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Derik de Bruin restated coverage on Zoetis with a Buy and a $60 price target.
10/11/16
STFL
10/11/16
NO CHANGE
STFL
Zoetis outlook positive despite cattle headwinds, says Stifel
Stifel analyst Jonathan Block says that Zoetis is facing a number of headwinds in cattle, including difficult comps and unfavorable cattle and milk prices. However, he thinks the company will be boosted in Q4 and into fiscal 2017 by easing comps and its "competitive" vaccine offering. Block says that the outlook for the company's companion animal and swine offerings remain positive, and he thinks the company's EPS can beat expectations over the next 12-24 months. Block keeps a Buy rating on the shares.
07/14/16
JEFF
07/14/16
NO CHANGE
JEFF
AbbVie remains Jefferies' Top Pick in Global Pharma
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his firm's Top Pick in Global Pharmaceuticals, followed by Eli Lilly (LLY), Novartis (NVS), GlaxoSmithKline (GSK) and Zoetis (ZTS). The analyst this morning upgraded GSK to Buy from Hold. Holford also remains positive on Roche (RHHBY), Abbott (ABT) and Pfizer (PFE). The analyst's least preferred names are Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Merck (MRK). The Q2 earnings season offers "few clear beat and raise" stories and looks weakest for AstraZeneca (AZN) against preliminary consensus, Holford tells investors in a pre-earnings research note.
09/07/16
FBCO
09/07/16
NO CHANGE
FBCO
Progressive, U.S. Silica and Zoetis added to US Focus List at Credit Suisse
Credit Suisse added Progressive (PGR), U.S. Silica (SLCA) and Zoetis (ZTS) to the US Focus List and removed Allison Transmission (ALSN) from the US Focus List and Sealed Air (SEE) from the US Focus List and Global Focus List
EVH Evolent Health

11/15/16
COWN
11/15/16
NO CHANGE
Target $35
COWN
Outperform
Evolent Health weakness offers attractive entry point, says Cowen
Cowen analyst Charles Rhyee believes the 10% pullback in Evolent Health shares since the election reflects concerns that repealing and replacing the ACA could mean there will be no more Medicaid expansion. However, he thinks the provision eliminating Medicaid expansion and the associated Federal Medical Assistance Percentages increase may not be included in the Republican ACA-repeal provisions. Also, Rhyee thinks a transition to value-based care will continue even if the ACA is repealed and replaced. He recommends buying amid the post-election weakness and reiterate his $35 price target and Outperform rating on the shares.
11/22/16
ADAM
11/22/16
NO CHANGE
Target $31
ADAM
Buy
Evolent Health remains a top pick at Canaccord
Canaccord analyst Richard Close had investor meetings with Evolent Health and came away with confidence that 2017 estimates are conservative. The analyst continues to call Evolent a to pick, citing its significant pipeline of new business, new client wins and penetration of existing clients, and the opportunity to triple its business within its existing client base. Close reiterated his Buy rating and $31 price target on Evolent Health shares.
11/16/16
WBLR
11/16/16
NO CHANGE
WBLR
Outperform
William Blair calls Evolent top small-cap alpha generation idea
William Blair analyst Ryan Daniels listed his top 10 reasons for why the recent pullback in shares of Evolent Health creates a good entry point. Much of the post-quarter weakness relates to the recent election results, as investors weigh the uncertainty created by a Republican-controlled White House and Congress along with the party's objective to immediately repeal and replace the Affordable Care Act, Daniels tells investors in a research note. The analyst believes the "movement to value-based care in the United States will continue apace" and has "strong" bipartisan support. He also believes Evolent Health's momentum "is quite strong." It is unlikely that the new administration will disrupt the insurance markets so much that tens of millions of Americans suddenly lose coverage in 2019, Daniels tells investors in a research note. He calls Evolent his top small-cap alpha generation idea over the next 12 months and reiterates an Outperform rating on the name.
11/21/16
LEER
11/21/16
NO CHANGE
Target $24
LEER
Outperform
Leerink continues positive on Evolent Health heading into 2017
Leerink analyst David Larsen continues to be positive on Evolent Health heading into 2017, and says that management has consistently delivered on promises, including five new partner relationships in 2016, steady organic growth in lives-on-platform from existing customers, a high degree of recurring revenue and steady improvement in EBITDA. The analyst reiterated an Outperform rating on the stock but lowered his price target on the shares to $24 from $28.
PACB Pacific Biosciences
$7.61

-0.09 (-1.17%)

08/18/16
CANT
08/18/16
NO CHANGE
Target $165
CANT
Speculative Buy
Thermo Fisher unlikely to acquire Illumina, says Cantor
Cantor Fitzgerald analyst Bryan Brokmeier believes it is unlikely that Thermo Fisher (TMO) will attempt to acquire Illumina (ILMN). Even if Thermo were to attempt a deal, the merger would be unlikely to close, Brokmeier tells investors in an intraday research note. If Illumina is a willing seller, however, Roche (RHHBY) may reconsider a bid, the analyst contends. He recommends investors stay on the sidelines with respect to Illumina shares. Brokmeier has a Hold rating on the name with a $165 price target. The analyst continues to believe Roche is the most likely acquirer of Pacific Biosciences (PACB).
08/04/16
08/04/16
NO CHANGE

On The Fly: After Hours Movers
UP AFTER EARNINGS: Pacific Biosciences (PACB), up 17%... MasTec (MTZ), up 9.6%... Aratana Therapeutics (PETX), up 9.2%... Lion's Gate (LGF), up 6.4%... Priceline (PCLN), up 5.7%... Ubiquiti (UBNT), up 5.5%... MercadoLibre (MELI), up 4.1%... Organovo (ONVO), up 3.9%... Kraft Heinz (KHC), up 3.3%... EOG Resources (EOG), up 2.8%... Monster Beverage (MNST), up 1.2%... TASER (TASR), up 1.2%... Take-Two (TTWO), up 0.9%... Activision Blizzard (ATVI), up 1%... BioMarin (BMRN), up 0.4%. ALSO HIGHER: Egalet (EGLT), up 31.2% after the company announced that an FDA advisory committee recommended approval of its ARYMO ER drug... Rackspace (RAX), up 17.6% after the Wall Street Journal reported that the company was near a takeover deal with a private equity buyer... Osiris (OSIR), up 8.5% after it said that the manuscript from its prospective trial using Grafix was published. DOWN AFTER EARNINGS: Hortonworks (HDP), down 26.2%... PDL BioPharma (PDLI), down 17.5%... FireEye (FEYE), down 15.8%... Sierra Wireless (SWIR), down 15.6%... Aquinox (AQXP), down 14.7%... Zynga (ZNGA), down 9.4%... Universal Display (OLED), down 8.2%... Weight Watchers (WTW), down 7.6%... Zillow Group (Z, ZG), down 5.5%... Arista Networks (ANET), down 4.5%... Noodles & Company (NDLS), down 4.3%... Merrimack (MACK), down 1.7%... Bankrate (RATE), down 1.7%.
04/22/16
CANT
04/22/16
NO CHANGE
CANT
Pacific Biosciences should be bought after strong Q1 results, says Cantor
Cantor recommends that investors buy the shares of Pacific Biosciences after the company reported stronger than expected Q1 results. The firm thinks that the company's increased guidance may be conservative, and it believes that the company could have at least 30 bookings in Q2. Cantor keeps an $18 price target and Buy rating on the shares.
04/18/16
PIPR
04/18/16
NO CHANGE
Target $11
PIPR
Neutral
Pacific Biosciences estimates lowered on Sequel checks at Piper Jaffray
Piper Jaffray analyst William Quirk lowered his Q1 estimates for Pacific Biosciences after his initial round of Sequel channel checks found six placements during the quarter compared to the 17 he modeled. Assuming Roche placed five systems, the Q1 total would come to 11, Quirk tells investors in a research note. The analyst keeps a Neutral rating on the shares with an $11 price target.
ARIA Acquired by TKPYY 2/17
$13.48

-0.32 (-2.32%)

11/03/16
11/03/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BioMarin (BMRN) initiated with a Buy at Deutsche Bank. 2. Ambev (ABEV) reinstated with an Equal Weight at Barclays. 3. ARIAD (ARIA) initiated with a Hold at Deutsche Bank. 4. Thomson Reuters (TRI) reinstated with a Neutral at JPMorgan. 5. Exelixis (EXEL) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage click here.
10/26/16
JEFF
10/26/16
NO CHANGE
Target $11
JEFF
Buy
ARIAD price target lowered to $11 from $13 at Jefferies
Jefferies analyst Eun Yang lowered her price target for ARIAD Pharmaceuticals to $11 following the recent scrutiny on Iclusig pricing. Iclusig's pricing scheme "has been overly aggressive," but there is a "clear therapeutic value" to the drug, Yang tells investors in a research note. She believes the company will likely need to modify its pricing strategy. Yang lowered her sales estimates by 23% in 2017 and beyond but keeps a Buy rating on ARIAD. William Blair this morning raised its price target for the shares to $15 from $12.
10/26/16
WBLR
10/26/16
NO CHANGE
Target $15
WBLR
Outperform
Unfazed by congressional inquiry, William Blair ups ARIAD target to $15
William Blair analyst Y. Katherine Xu raised her price target for ARIAD Pharmaceuticals to $15 from $12 on higher sales expectations. The analyst upped her peak global sales forecast of Iclusig to $1.1B from $900M, based on projected increased second-line uptake in 2019 and beyond. Xu also increased her estimate for global peak sales of brigatinib to $790M from $640M, based on a competitive profile analysis after the European Society of Medical Oncology meeting. Her model values Iclusig in chronic myelogenous leukemia at $9 per share and brigatinib at $6 per share, with a 90% probability of success in ALK+ non-small-cell lung cancer. Xu keeps an Outperform rating on shares of ARIAD. She believes the recent congressional inquiry on Iclusig pricing is unlikely to affect her peak sales estimates. ARIAD remains an attractive takeout candidate in the 2017-2018 timeframe "given the pending brigatinib approval and the strength of the portfolio," Xu tells investors in a research note. ARIAD in pre-market trading is up 14c to $9.48.
11/03/16
DBAB
11/03/16
INITIATION
Target $9.5
DBAB
Hold
ARIAD initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Andrew Peters started ARIAD Pharmaceuticals with a Hold rating and $9.50 price target. Headline risk from pricing could overshadow any positive pipeline news flow until the issue is resolved, Peters tells investors in a research note. He expects the stock to be range-bound in the near-term.
SAGE Sage Therapeutics
$50.11

-0.69 (-1.36%)

11/14/16
STFL
11/14/16
INITIATION
Target $50
STFL
Buy
SAGE Therapeutics initiated with a Buy at Stifel
Stifel analyst Katherine Breedis initiated SAGE Therapeutics with a Buy and a $50 price target.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/04/16
LEER
10/04/16
INITIATION
Target $68
LEER
Outperform
SAGE Therapeutics reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of SAGE Therapeutics with an Outperform rating and $68 price target.
11/03/16
BMOC
11/03/16
NO CHANGE
Target $57
BMOC
Outperform
SAGE Therapeutics pipeline on track for 'robust' 2017, says BMO Capital
After the company reported Q3 results, BMO Capital analyst Gary Nachman says SAGE Therapeutics has clarified its strategy to advance as a multi-product neuropsych portfolio company with a pipeline full of catalysts including eight clinical data readouts expected in 2017 across neurology, mood disorders and movement disorders. The analyst believes earnings should be less of a focus as the company continues to move forward its pipeline and continues to see risk/reward as favorable into the super-refractory status epilepticus data. He reiterates an Outperform rating and $57 price target on the shares.
EW Edwards Lifesciences

12/01/16
JPMS
12/01/16
NO CHANGE
Target $120
JPMS
Overweight
JPMorgan sees Edwards stock performance to be driven by TMVR, not TAVR
JPMorgan analyst Michael Weinstein said he has "no concerns" about the transcatheter aortic valve replacement, or TAVR, market, which he expects to accelerate both in the U.S. and outside of it from Q3 to Q4. He added that he views all of the talk about the health of the TAVR market following Edwards Lifesciences' quarter as "nonsense." That said, progress on the mitral side, or TMVR, will dictate Edwards' stock performance over the next 12 months, not TAVR, Weinstein tells investors. The TMVR market may be closer than thought and the answer to the question of whether CardiAQ will be ready for approval in Europe by the end of 2018 "has huge implications for the stock," said Weinstein, who lowered his price target on Edwards shares to $120 from $135 but keeps an Overweight rating on the stock.
11/15/16
LEER
11/15/16
NO CHANGE
LEER
Edwards Lifesciences, Medtronic selloff overdone, says Leerink
Leerink analyst Danielle Antalffy notes that both Edwards Lifesciences (EW) and Medtronic (MDT) traded down in reaction to a presentation of the German Aortic Valve Registry data in intermediate risk patients. However, she believes the selloff is overdone, with no change to her estimated total addressable transcatheter aortic valve replacement, or TAVR, market opportunity as there are key baseline characteristic differences between both the surgical valve and TAVR groups that skews the data, and randomized controlled clinical trial data trumps registry data.
11/14/16
EVER
11/14/16
NO CHANGE
EVER
Medtronic, Edwards Lifesciences defended at Evercore ISI
11/08/16
NORL
11/08/16
UPGRADE
NORL
Outperform
Edwards Lifesciences upgraded to Outperform from Market Perform at Northland
Northland upgraded Edwards Lifesciences to Outperform saying the Q3 related selloff provides a tactical buying opportunity and maintained its $105 price target on shares.
NVRO Nevro

11/15/16
JMPS
11/15/16
NO CHANGE
JMPS
Nevro weakness creates buying opportunity, says JMP Securities
After traveling with Nevro's management, JMP Securities analyst David Trukaly thinks that its fundamentals "remain strong." The analyst says that the company's Senza technology is "differentiated," and he thinks that it will continue to gain share "for years to come." The analyst reiterates a $110 price target and an Outperform rating on the shares.
11/08/16
JPMS
11/08/16
NO CHANGE
Target $106
JPMS
Overweight
JPMorgan recommends 'opportunistic buying' of Nevro shares
Nevro reported a "solid" beat in Q3, but it is likely not enough to appease the Street, JPMorgan analyst Michael Weinstein tells investors in a post-earnings research note. The analyst remains confident in the company's "share and sales trajectory" as well as his underlying thesis on the shares. Weinstein recommends "opportunistic buying" on today's selloff and reiterates an Overweight rating on Nevro. He lowered his price target for the shares to $106 from $112.
11/08/16
LEER
11/08/16
NO CHANGE
Target $100
LEER
Outperform
Nevro price target lowered to $100 from $120 at Leerink
Leerink analyst Danielle Antalffy lowered her price target for Nevro to $100 from $120 after the company reported Q3 results. Nonetheless, the analyst believes the long-term growth trajectory for Nevro is unchanged and would recommend buying shares on weakness. He reiterates an Outperform rating on the shares.
10/24/16
JPMS
10/24/16
NO CHANGE
Target $112
JPMS
Overweight
Nevro price target raised to $112 from $100 at JPMorgan
JPMorgan analyst Michael Weinstein raised his price target for Nevro to $112 saying his fourth physician survey indicates that Senza's U.S. launch continues to track well ahead of Street expectations. The number of physicians that have trialed Senza continues to grow, Weinstein tells investors in a research note. He keeps an Overweight rating on the shares.
KTWO K2M Group
$18.80

0.11 (0.59%)

11/16/16
PIPR
11/16/16
NO CHANGE
PIPR
Piper says NuVasive, Novadaq pullbacks overdone
Piper Jaffray analyst Matt O'Brien views the post-earnings pullbacks in shares of NuVasive (NUVA) and Novadaq (NVDQ) as overdone. The analyst believes the stocks are disconnected from the intrinsic value of the companies. O'Brien also sees further room to run for shares of K2M Group (KTWO) and ZELTIQ (ZLTQ).
08/25/16
PIPR
08/25/16
NO CHANGE
PIPR
K2M Group has positive read through from distributor results, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says that K2M's Australian distributor, LifeHealthcare, reported higher than expected fiscal 2016 revenue. The analyst adds that the distributor was a major factor behind the lowering of K2M's guidance earlier this year. He thinks that K2M's valuation is attractive and keeps an Overweight rating on the shares.
10/10/16
RBCM
10/10/16
INITIATION
RBCM
Outperform
K2M Group initiated with an Outperform at RBC Capital
RBC Capital analyst Glenn Novarro started K2M with an Outperform rating and a target of $23.
11/11/16
PIPR
11/11/16
NO CHANGE
PIPR
Overweight
K2M should be bought on any stock sale selloff, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien recommends using any weakness in K2M Group from Welsh Carson's 4.5M share sale as a buying opportunity. The analyst believes the sale does not speak to any fundamental weakness in the story. He keeps an Overweight rating on K2M Group.

TODAY'S FREE FLY STORIES

NVS

Novartis

$87.21

0.21 (0.24%)

, CMCSA

Comcast

$42.44

-0.45 (-1.05%)

20:25
01/23/18
01/23
20:25
01/23/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NVS

Novartis

$87.21

0.21 (0.24%)

CMCSA

Comcast

$42.44

-0.45 (-1.05%)

GE

General Electric

$16.89

0.72 (4.45%)

UTX

United Technologies

$136.03

0.82 (0.61%)

ABT

Abbott

$59.23

-0.34 (-0.57%)

GD

General Dynamics

$207.48

-0.72 (-0.35%)

ITW

Illinois Tool Works

$173.06

-0.33 (-0.19%)

NSC

Norfolk Southern

$151.66

0.19 (0.13%)

BHGE

Baker Hughes

$35.82

0.27 (0.76%)

PGR

Progressive

$57.05

-1.17 (-2.01%)

RCL

Royal Caribbean

$127.22

-1.48 (-1.15%)

SWK

Stanley Black & Decker

$173.89

-1.34 (-0.76%)

ROK

Rockwell Automation

$204.69

0.76 (0.37%)

NTRS

Northern Trust

$106.89

-0.54 (-0.50%)

GWW

Grainger

$229.45

-0.41 (-0.18%)

ROL

Rollins

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 08

    Feb

  • 16

    Feb

  • 02

    Mar

  • 23

    Apr

  • 17

    May

CERS

Cerus

$4.33

0.14 (3.34%)

19:39
01/23/18
01/23
19:39
01/23/18
19:39
Conference/Events
Cerus to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 26

    Feb

XPER

Xperi

$22.85

0.35 (1.56%)

19:26
01/23/18
01/23
19:26
01/23/18
19:26
Conference/Events
Xperi to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$7.86

-0.1 (-1.26%)

19:14
01/23/18
01/23
19:14
01/23/18
19:14
Upgrade
McDermott rating change  »

McDermott upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

, ERJ

Embraer

$24.13

-0.34 (-1.39%)

19:08
01/23/18
01/23
19:08
01/23/18
19:08
Periodicals
Bombardier invokes Embraer in Boeing trade dispute, Globe and Mail says »

Bombardier (BDRBF) says…

BDRBF

Bombardier

ERJ

Embraer

$24.13

-0.34 (-1.39%)

BA

Boeing

$335.59

-2.41 (-0.71%)

DAL

Delta Air Lines

$59.93

-0.2 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

GSBC

Great Southern Bancorp

$52.00

0.45 (0.87%)

19:01
01/23/18
01/23
19:01
01/23/18
19:01
Earnings
Great Southern Bancorp reports preliminary Q4 EPS 86c, consnesus 83c »

Reports preliminary Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

UUUU

Energy Fuels

$1.72

0.035 (2.08%)

18:48
01/23/18
01/23
18:48
01/23/18
18:48
Hot Stocks
Energy Fuels names Mark S. Chalmers president and CEO »

Energy Fuels announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

18:15
01/23/18
01/23
18:15
01/23/18
18:15
General news
Breaking General news story  »

Chicago Federal Reserve…

RBS

RBS

$8.46

-0.02 (-0.24%)

18:10
01/23/18
01/23
18:10
01/23/18
18:10
Periodicals
RBS plans to leave London headquarters by end of 2019, Reuters reports »

The Royal Bank of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROX

Tronox

$21.88

0.07 (0.32%)

18:09
01/23/18
01/23
18:09
01/23/18
18:09
Hot Stocks
Tronox files lawsuit to prevent FTC from blocking proposed Cristal acquisition »

Tronox filed a lawsuit in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBNK

United Financial

$17.92

-0.03 (-0.17%)

18:00
01/23/18
01/23
18:00
01/23/18
18:00
Hot Stocks
United Financial reports Q4 provision for loan losses $2.3M »

Reports Q4 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

UBNK

United Financial

$17.92

-0.03 (-0.17%)

17:59
01/23/18
01/23
17:59
01/23/18
17:59
Earnings
United Financial reports Q4 EPS with items 19c, consensus 30c »

Companies must recognize…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SPY

SPDR S&P 500 ETF Trust

$283.29

0.6 (0.21%)

, SPX

S&P 500

17:55
01/23/18
01/23
17:55
01/23/18
17:55
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Senate confirms Jerome…

SPY

SPDR S&P 500 ETF Trust

$283.29

0.6 (0.21%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:55
01/23/18
01/23
17:55
01/23/18
17:55
Conference/Events
Federal Reserve Bank of Chicago President participates in a discussion »

Chicago Federal Reserve…

HESM

Hess Midstream Partners

$21.75

0.45 (2.11%)

17:46
01/23/18
01/23
17:46
01/23/18
17:46
Hot Stocks
Hess Midstream Partners raises quarterly dividend 3.6% to 32.2c per unit »

The distribution will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 26

    Feb

GWB

Great Western

$44.29

0.53 (1.21%)

17:33
01/23/18
01/23
17:33
01/23/18
17:33
Hot Stocks
Great Western announces financial impact resulting from Tax Cuts and Jobs Act »

Great Western Bancorp,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

ARAY

Accuray

$5.20

0.05 (0.97%)

, TSS

TSYS

$83.92

0.17 (0.20%)

17:27
01/23/18
01/23
17:27
01/23/18
17:27
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

ARAY

Accuray

$5.20

0.05 (0.97%)

TSS

TSYS

$83.92

0.17 (0.20%)

CERS

Cerus

$4.33

0.14 (3.34%)

NTIP

Network-1 Technologies

$2.60

0.1 (4.00%)

GOOG

Alphabet

$1,169.97

14.16 (1.23%)

GOOGL

Alphabet Class A

$1,176.17

12.01 (1.03%)

QGEN

Qiagen

$33.55

0.5 (1.51%)

SIRI

SiriusXM

$5.68

0.03 (0.53%)

VLO

Valero

$98.69

-0.26 (-0.26%)

UAL

United Continental

$77.97

1.1 (1.43%)

NAVI

Navient

$13.44

-0.08 (-0.59%)

CREE

Cree

$35.02

-1.67 (-4.55%)

COF

Capital One

$105.71

0.22 (0.21%)

TXN

Texas Instruments

$119.89

0.45 (0.38%)

PBYI

Puma Biotechnology

$90.90

-3.05 (-3.25%)

SIGM

Sigma Designs

$7.00

0.025 (0.36%)

FPRX

Five Prime

$22.43

0.14 (0.63%)

RCKT

Rocket Pharmaceuticals

$15.19

1.92 (14.47%)

TK

Teekay Corp.

$10.74

0.05 (0.47%)

SBBP

Strongbridge Biopharma

$8.70

0.25 (2.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    Mar

  • 21

    Mar

  • 24

    Jan

  • 24

    Jan

  • 25

    Jan

  • 26

    Jan

UAL

United Continental

$77.97

1.11 (1.44%)

17:25
01/23/18
01/23
17:25
01/23/18
17:25
Earnings
United Continental sees FY18 EPS $6.50-$8.50, consensus $6.97 »

Sees FY18 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

17:25
01/23/18
01/23
17:25
01/23/18
17:25
Conference/Events
The Chicago Council on Global Affairs to hold a panel discussion »

The Chicago Council on…

MULE

MuleSoft

$25.08

-0.31 (-1.22%)

17:21
01/23/18
01/23
17:21
01/23/18
17:21
Initiation
MuleSoft initiated at Nomura Instinet »

MuleSoft initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

MDB

MongoDB

$28.83

0.02 (0.07%)

17:19
01/23/18
01/23
17:19
01/23/18
17:19
Initiation
MongoDB initiated at Nomura Instinet »

MongoDB initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$77.97

1.1 (1.43%)

17:19
01/23/18
01/23
17:19
01/23/18
17:19
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United sees FY19 and FY20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

UAL

United Continental

$77.97

1.1 (1.43%)

17:18
01/23/18
01/23
17:18
01/23/18
17:18
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United sees FY18 CASM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

APTI

Apptio

$24.39

0.02 (0.08%)

17:17
01/23/18
01/23
17:17
01/23/18
17:17
Initiation
Apptio initiated at Nomura Instinet »

Apptio initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

VMW

VMware

$137.96

1.27 (0.93%)

17:16
01/23/18
01/23
17:16
01/23/18
17:16
Initiation
VMware initiated at Nomura Instinet »

Nomura starts VMware with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.